MENLO PARK, Calif.–(BUSINESS WIRE)–Personalis, Inc., a leader in advanced genomics for precision oncology,
today announced that they are scheduled to present at the upcoming ICI
Europe Summit 2018 in Berlin, Germany on Wednesday, November 28, 2018 at
9.30 AM, CET.
presentation, entitled “Enabling Multidimensional Biomarker
Discovery: Interrogating the Tumor, its Microenvironment, and
Neoantigens with ACE ImmunoID,” will discuss how the Personalis Platform
overcomes the limitations associated with conventional NGS approaches
that are used in translational research and the clinical development of
new oncology therapeutics. The presentation will also introduce
Personalis’ new ImmunoID NeXT Platform™.
NeXT is the first and only platform to provide comprehensive
analysis of both a tumor and its microenvironment from a single sample.
The platform can be used to investigate the key tumor- and
immune-related areas of cancer biology; consolidating multiple oncology
biomarker assays into one. This maximizes the biological information
that can be generated from a precious tumor specimen.
The presentation will be delivered by Erin Newburn, PhD, Associate
Director, Field Applications Scientist.
About Personalis, Inc.
Personalis, Inc. is a leader in advanced genomics for precision oncology
translational research and clinical trials, dedicated to enabling the
development of the next generation of oncology therapeutics. The
company’s ImmunoID NeXT Platform comprehensively characterizes the tumor
and the tumor microenvironment, facilitating the analysis of key
predictive and investigational oncology biomarkers from a single sample.
The Personalis Clinical
Laboratory is GxP aligned as well as CLIA’88-certified and
CAP-accredited. For more information, please visit www.personalis.com
and follow Personalis on Twitter (@PersonalisInc).